![]() |
市場調查報告書
商品編碼
2106662
經橈動脈通路產品:市場洞察、競爭格局及市場預測 - 2034 年Transradial Access Products - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
經橈動脈通路產品是指用於鼠蹊部建立經腕部經皮動脈通路(而非腹股溝股動脈通路)的專用導管、導管導引線、鞘套及輔助止血裝置。這使得冠動脈攝影術、經皮冠狀動脈介入治療、周邊血管介入治療和其他基於導管的介入治療成為可能,並顯著減少了通路部位的出血和血管併發症。由於橈動脈比股動脈更細更淺,因此經橈動脈通路的手術需要採用特殊設計的低輪廓鞘套、親水塗層、纖細鞘套技術、抗扭轉導管導引線以及專用壓迫和止血裝置,以最大限度地減少橈動脈痙攣或閉塞,同時保持手術成功率。本市場依產品類型分為導管、導管導引線、鞘套及其他通路及止血附件。依應用領域分為診斷和介入性心臟病學、藥物輸注、輸血和其他血管通路應用。依最終用戶分類,產品可分為醫院和診所、門診手術中心以及其他醫療機構。依地理分類,產品可分為北美、歐洲、亞太地區以及世界其他地區。受心血管疾病盛行率上升、強力的臨床證據支持橈動脈通路方案、人口老化以及門診心血管護理快速發展的推動,橈動脈通路產品已成為現代微創介入醫學的基礎技術。
徑向接入產品的主要市場促進因素
推動經橈動脈通路產品市場成長的因素
市場促進因素
全球心血管疾病負擔日益加重,PCI手術數量不斷增加。
經橈動脈通路產品市場成長的最主要促進因素是冠狀動脈疾病的持續增加,以及由此導致的全球冠動脈攝影術和經皮冠狀動脈介入治療(PCI)手術數量的成長。橈動脈通路手術在全球範圍內迅速普及,目前已佔發達醫療體系中經皮冠狀動脈介入治療手術的大多數,這反映出其在臨床實踐中的廣泛應用。冠狀動脈疾病導致的死亡率和住院率不斷上升,包括澳洲等已開發市場報告的成長,推動需要導管介入診斷和治療的患者群體持續擴大。由於每次手術都需要專用的通路導管、導管導引線和鞘套,因此手術數量的增加直接轉化為對醫療設備的持續需求。隨著人口老化導致心血管疾病盛行率持續上升,對經橈動脈通路產品的需求將直接成長,為2034年之前的市場成長奠定基礎。
支持半徑優先方案的臨床證據和指南
大量且不斷成長的臨床證據支持橈動脈通路優於股動脈通路,這是推動該市場成長的主要動力。隨機對照試驗、科學聲明以及美國心臟協會(AHA)關於橈動脈冠動脈攝影術和介入治療最佳實踐的指南均一致表明,橈動脈通路可減少出血、降低血管併發症、允許患者更早轉運,並顯著降低住院成本。成本效益研究表明,採用橈動脈通路進行經皮冠狀動脈介入治療(PCI)可節省數十萬美元的醫院成本,對於出血風險高的患者,節省的成本甚至更高。隨著「橈動脈優先方案」在專業學會和醫院品質管理計畫中日益確立為標準治療方案,採用橈動脈通路的介入手術數量持續成長,直接擴大了預測期內經橈動脈通路產品的潛在市場。
市場限制因素
儘管橈動脈通路產品市場發展動力強勁,但仍面臨許多限制因素。橈動脈痙攣和閉塞仍然是臨床上重要的併發症,據報道,高達五分之一的患者會出現痙攣,而閉塞發生率僅為幾個百分點,這可能會限制橈動脈通路在某些複雜和大口徑手術中的可行性,因此需要不斷改進器械和技術。橈動脈直徑相對較小,因此從股動脈通路過渡到橈動脈通路的醫生需要一定的訓練時間。此外,一些發展中地區缺乏訓練有素、精通橈動脈通路的介入性心臟病專家和放射科醫生,這限制了橈動脈通路技術的普及。專用橈動脈通路器械和止血器械的高成本和持續維護需求,可能會成為小規模醫院和價格敏感型市場的障礙。不同地區的醫保償付機制和專用橈動脈技術的應用仍然存在差異,而依賴少數醫療設備製造商的供應鏈也帶來了價格和供應風險。儘管心血管疾病負擔日益加重、臨床指南的支持以及門診護理的擴展等潛在促進因素依然強勁,但這些臨床、人力、成本和償付方面的障礙加在一起,減緩成長速度。
Transradial Access Products Market Summary
Transradial access products are specialized catheters, guidewires, sheaths, and adjunct hemostasis devices used to gain percutaneous arterial access through the radial artery in the wrist rather than the femoral artery in the groin, enabling coronary angiography, percutaneous coronary intervention, peripheral vascular procedures, and other catheter-based interventions with substantially lower access-site bleeding and vascular complications. Because the radial artery is smaller and more superficial than the femoral artery, transradial procedures require purpose-built low-profile sheaths, hydrophilic coatings, slender-sheath technology, kink-resistant guidewires, and dedicated compression and hemostasis devices to minimize radial artery spasm and occlusion while preserving procedural success. The market is organized by product across catheters, guidewires, sheaths, and other access and hemostasis accessories; by application across diagnostic and interventional cardiology, drug administration, blood transfusion, and other vascular access uses; by end-user across hospitals and clinics, ambulatory surgical centers, and other care settings; and by geography across North America, Europe, Asia-Pacific, and the Rest of the World. Driven by rising cardiovascular disease prevalence, strong clinical evidence favoring radial-first protocols, an aging population, and rapid growth of outpatient cardiovascular care, transradial access products have become a foundational technology underpinning modern minimally invasive interventional medicine.
Transradial Access Products Market Key Growth Drivers
Key Companies in Transradial Access Products Market
The competitive landscape is led by the following active device manufacturers:
Factors Contributing to the Growth of the Transradial Access Products Market
Market Drivers
Rising Global Cardiovascular Disease Burden and PCI Volumes
The most powerful driver of the Transradial Access Products market is the sustained rise in coronary artery disease and the resulting growth in coronary angiography and percutaneous coronary intervention volumes worldwide. Global utilization of transradial procedures has expanded rapidly, with radial access now accounting for a majority of percutaneous coronary interventions across developed healthcare systems, reflecting broad clinical acceptance. Rising incidence of coronary heart disease deaths and hospitalizations, including documented increases across developed markets such as Australia, continues to expand the pool of patients requiring catheter-based diagnosis and treatment. Because every procedure requires a dedicated access catheter, guidewire, and sheath, this procedural growth translates directly into recurring device demand. As cardiovascular disease prevalence continues to climb alongside aging populations, demand for transradial access products expands directly, anchoring market growth through 2034.
Clinical Evidence and Guideline Support for Radial-First Protocols
A deep and growing body of clinical evidence favoring transradial over transfemoral access is a central growth engine for the market. Randomized trials and scientific statements, including guidance from the American Heart Association on best practices for transradial coronary angiography and intervention, consistently demonstrate reduced bleeding, fewer vascular complications, faster patient mobilization, and materially lower hospital costs with radial access. Cost-effectiveness research has shown hospital savings exceeding several hundred dollars per PCI with radial access, with savings compounding further among patients at higher bleeding risk. As professional societies and hospital quality programs increasingly codify radial-first protocols as standard of care, procedural volumes performed radially continue to rise, directly enlarging the addressable market for transradial access products through the forecast period.
Market Restraints
Despite strong momentum, the Transradial Access Products market faces material constraints. Radial artery spasm and occlusion remain clinically significant complications, reported in up to a fifth of patients for spasm and several percent for occlusion, and can limit the feasibility of transradial access in certain complex or large-bore procedures, requiring continued device and technique refinement. The relatively small caliber of the radial artery imposes a learning curve for operators transitioning from femoral technique, and a shortage of trained interventional cardiologists and radiologists proficient in radial access constrains adoption in some developing regions. High cost and ongoing maintenance requirements for specialized radial access and hemostasis devices can be a barrier for smaller hospitals and price-sensitive markets. Reimbursement frameworks and adoption of newer radial-specific technologies remain uneven across geographies, and supply-chain dependence on a concentrated group of device manufacturers introduces pricing and availability risk. Together, these clinical, workforce, cost, and reimbursement barriers temper the pace of growth, even as the underlying drivers of cardiovascular disease burden, guideline support, and outpatient care expansion remain firmly intact.
Transradial Access Products Market Segment Analysis
The Transradial Access Products by Market by Product (Catheter, Guidewire, Sheath, and Others), Application (Diagnostic & Interventional, Drug Administration, Blood Transfusion, and Others), End-User (Hospitals & Clinics, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).
By Product
Dominant Subsegment: Catheter.
Dominant: Catheter ~ 38%
The catheter segment accounted for 38% of the transradial access products market in 2025. Catheters are the leading product category because every diagnostic and interventional radial procedure requires one or more specialized diagnostic or guiding catheters to navigate from the wrist to the coronary or peripheral vasculature, and because catheters are consumed with every single case, generating the highest and most consistent unit volumes of any product category. The breadth of catheter shapes and sizes required to accommodate diverse anatomies and procedure types, combined with continuous innovation in torque control, kink resistance, and trackability, sustains great and dependable demand for catheter manufacturing and distribution. Sheaths are the fastest-growing product category, propelled by the rapid adoption of slender, hydrophilic-coated introducer sheaths that enable larger-bore procedures through smaller punctures, while guidewires remain an essential, high-volume complementary product. Nonetheless, the sheer procedural necessity and volume of catheter use secures the segment's leadership across the forecast period.
By Application
Dominant Subsegment: Diagnostic & Interventional.
Dominant: Diagnostic & Interventional ~ 72%
The diagnostic & interventional segment accounted for 72% of the Transradial Access Products market in 2025. Diagnostic and interventional cardiology and radiology procedures, including coronary angiography, percutaneous coronary intervention, and peripheral vascular interventions, are the leading application because they generate the highest procedural volumes and the broadest, most consistent use of dedicated access catheters, guidewires, and sheaths. The well-documented safety and cost benefits of radial access relative to femoral access have made it the default approach for the large majority of diagnostic and interventional cardiac catheterization procedures across developed healthcare systems. Drug administration and blood transfusion applications, which use radial and related vascular access for medication delivery and blood-product administration, represent smaller but steady demand pools. While drug administration is growing quickly as vascular access standardization extends beyond cardiology, the volume, frequency, and clinical centrality of diagnostic and interventional cardiovascular procedures secure this segment's clear leadership across the forecast period.
Transradial Access Products Market Region Analysis
Dominant Region: North America
Dominant: North America ~ 44% (Largest)
North America accounted for 44% of the global Transradial Access Products market revenue in 2025, representing the highest regional market share globally. The region's dominance reflects a mature interventional cardiology ecosystem, high procedural volumes, strong reimbursement frameworks, and rapid, well-documented adoption of radial-first protocols across leading health systems in the United States and Canada. North America hosts the largest concentration of high-volume cardiac catheterization laboratories and benefits from the presence of major device manufacturers headquartered in the region, supporting rapid access to the latest low-profile sheath and catheter innovations. Strong clinical-research infrastructure, favorable reimbursement for outpatient cardiovascular procedures, and growing adoption of transradial access in ambulatory surgical centers continue to reinforce the region's leadership across the forecast period.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Transradial Access Products market. The region's elevated CAGR is driven by rising cardiovascular disease incidence, rapid expansion of cardiac catheterization infrastructure, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China continues to expand its network of cardiac catheterization laboratories and interventional cardiology training programs, Japan maintains a long-standing and mature radial-access clinical culture, India is scaling low-cost domestic manufacturing and interventional cardiology capacity, and Australia benefits from a well-established interventional cardiology base. Government healthcare investment, an expanding population living with cardiovascular disease, and rising awareness of the clinical benefits of radial access are accelerating adoption across the region, positioning Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 44% of the global Transradial Access Products market revenue in 2025. The United States dominates on the strength of its high-volume cardiac catheterization infrastructure, favorable reimbursement environment, and early, well-documented adoption of radial-first protocols, while the presence of leading device manufacturers and growing use of transradial access in ambulatory surgical centers reinforce its leadership.
Europe
Europe is a large and advanced regional market, supported by well-established interventional cardiology guidelines, high radial-access adoption rates in countries such as Germany, Spain, and Portugal, and strong regulatory frameworks under CE marking. Government initiatives such as NICE and NHS Innovation Accelerator support in the United Kingdom, alongside growing single-use radial kit adoption to minimize infection risk, reinforce the region's role in supplying both diagnostic and interventional transradial access programs across Germany, France, the United Kingdom, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising cardiovascular disease incidence, rapid cardiac catheterization infrastructure build-out, and growing healthcare investment across China, Japan, India, South Korea, and Australia. China's expanding cath-lab network, Japan's mature radial-access clinical culture, India's low-cost manufacturing base, and South Korea's advanced interventional cardiology adoption are accelerating regional market growth and clinical training activity.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding cardiac catheterization and healthcare infrastructure, rising demand for minimally invasive diagnostic and interventional cardiovascular care, and efforts to align regulatory frameworks with global standards are gradually broadening access, while growing physician training in radial technique and international partnerships support the build-out of regional interventional cardiology capacity.
Transradial Access Products Market Competitive Landscape
The Transradial Access Products market is classified as Moderately Concentrated. A group of large, diversified medical device manufacturers with global distribution reach, including Terumo Medical Corporation, Medtronic, Merit Medical Systems, and Edwards Lifesciences Corporation, secures large hospital contracts and anchors the top tier, while specialized and regionally focused providers such as AngioDynamics, SCW Medicath, Tianck Medical, Shanghai Kindly Medical Instruments, Colibri Heart Valve, and Nipro Medical Corporation compete through niche product breadth, regional manufacturing scale, and targeted clinician relationships, increasing competition in fast-growing emerging markets.
The competitive landscape can be evaluated across the following dimensions:
Transradial Access Products Market Recent Developmental Activities
In August 2025, Merit Medical Systems announced the U.S. commercial launch of the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Securement Technology, a low-profile sheath designed to reduce radial artery spasm and occlusion while improving sheath retention during radial access procedures. Strategic significance: Strengthens Merit's Access portfolio and reinforces its radial-first product strategy.
In October 2025, Merit Medical Systems acquired the assets of Radial Assist, including the RAD BOARD, RAD BOARD XTRA, RAD TRAC, and RAD REST radial procedural support devices. Strategic significance: Expands Merit's radial-access accessory portfolio and procedural support offerings.
Transradial Access Products Market Segmentation
Transradial Access Products Market by Product
Transradial Access Products Market by Application
Transradial Access Products Market by End User
Transradial Access Products Market by Geography
Key Takeaways from the Transradial Access Products Market Report Study
Target audience who can benefit from this transradial access products market report study
Q1. What is the growth rate of the Transradial access products market?
The transradial access products market is projected to expand at a CAGR of 7.9% during the forecast period from 2026-2034.
Q2. What is the market size of the Transradial Access Products market?
The Transradial Access Products market is estimated at USD 2.48 billion in 2025 and is projected to reach USD 4.92 billion by 2034.
Q3. Which region dominates the Transradial Access Products market?
North America dominated the Transradial Access Products market with a 44% share of global revenue in 2025, supported by a mature interventional cardiology ecosystem, high procedural volumes, strong reimbursement frameworks, and rapid adoption of radial-first protocols. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Transradial Access Products market?
The principal drivers are the rising global cardiovascular disease burden and growing coronary intervention volumes; strong clinical evidence and guideline support for radial-first protocols; continuous innovation in low-profile, hydrophilic sheath and hemostasis technology; rapid expansion of ambulatory surgical centers and outpatient cardiovascular care; and a growing geriatric population requiring repeated vascular access.
Q5. Who are the major players in the Transradial Access Products market?
The major players include AngioDynamics, Terumo Medical Corporation, Medtronic, SCW Medicath Ltd., Tianck Medical Co., Ltd., Edwards Lifesciences Corporation, Shanghai Kindly Medical Instruments Co., Ltd., Colibri Heart Valve, Merit Medical Systems, and Nipro Medical Corporation, among other active providers profiled in the Competitive Landscape section. Terumo Medical Corporation, Medtronic, Merit Medical Systems, and Edwards Lifesciences Corporation lead through global distribution networks and broad interventional product portfolios.
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.